Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Fig. 5

Case analysis of patient with dynamic ctDNA detection at baseline, after two cycles of treatment, and after disease progression. A The timeline, treatment history, and radiographic response to treatment of the patient P57. B The changes of bITH score, tumor size, and detected somatic mutations at baseline and after two cycles of therapy in patient P57. Hierarchical clustering method was used to cluster somatic mutations detected at multiple time points. bITH, blood-based intratumor heterogeneity; SD, stable disease; PD, progressive disease; MSAF, maximum somatic allele frequency; MAF, mutant allele frequency

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us